![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 36 36" xmlns="http://www.w3.org/2000/svg"><path d="M 19 18 L 36 18 L 36 19 L 19 19 L 19 36 L 18 36 L 18 19 L 0 19 L 0 18 L 18 18 L 18 0 L 19 0 Z" fill="rgb(255, 255, 255)" height="36px" id="zGS8DWzeh" width="36px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 36 36" xmlns="http://www.w3.org/2000/svg"><path d="M 19 18 L 36 18 L 36 19 L 19 19 L 19 36 L 18 36 L 18 19 L 0 19 L 0 18 L 18 18 L 18 0 L 19 0 Z" fill="rgb(255, 255, 255)" height="36px" id="SCKJPsPDW" width="36px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 575 575" xmlns="http://www.w3.org/2000/svg"><path d="M 287.5 575 C 446.282 575 575 446.282 575 287.5 C 575 128.718 446.282 0 287.5 0 C 128.718 0 0 128.718 0 287.5" fill="transparent" height="575px" id="XINTwJ_kr" stroke-dasharray="2,6" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(255, 255, 255)" width="575px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 437 437" xmlns="http://www.w3.org/2000/svg"><path d="M 437 218.5 C 437 97.826 339.174 0 218.5 0 C 97.826 0 0 97.826 0 218.5 C 0 339.174 97.826 437 218.5 437" fill="transparent" height="437px" id="x4TBJrhbE" stroke-dasharray="2,6" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(255, 255, 255)" width="437px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 353 705" xmlns="http://www.w3.org/2000/svg"><path d="M 0 705 C 194.68 705 352.5 547.18 352.5 352.5 C 352.5 157.82 194.68 0 0 0" fill="transparent" height="705px" id="i3oYFU0c2" stroke-dasharray="2,6" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(255, 255, 255)" width="352.5px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 2884 1" xmlns="http://www.w3.org/2000/svg"><path d="M 1442 0 L 0 0" fill="rgb(255, 255, 255)" height="1px" id="Sh6EUmXq2" stroke-dasharray="2,6" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgb(255, 255, 255)" transform="translate(0 0.5)" width="1442px"/><path d="M 1442 0 L 0 0" fill="rgb(255, 255, 255)" height="1px" id="uUTlaGEFM" stroke-dasharray="2,6" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgb(255, 255, 255)" transform="translate(1440 0.5)" width="1442px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 1 900" xmlns="http://www.w3.org/2000/svg"><path d="M 0 0 L 0 900" fill="transparent" height="900px" id="n9VS7prGc" stroke-dasharray="2,6" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgb(255, 255, 255)" transform="translate(0.5 0)" width="1px"/></svg>)
Semaglutide is a GLP-1 receptor agonist designed to work with your body's own appetite signaling. It may help support reduced cravings and a greater sense of fullness between meals. Enhanced delivers it with clinician oversight and a treatment plan tailored to your goals and response.
Physician monitored
Subcutaneous injection
Individualized to each person
Frequency determined by your physician
Medication, clinician, follow-ups
What you
can expect
A Protocol Built Around How Your Body Actually Responds
GUIDED DOSING
PROTOCOL
Your clinician sets your starting dose and titration schedule around your goals, your tolerance, and how you respond. Not a generic chart. Adjustments come from labs and how you're tolerating.
SUPPORTS APPETITE
REGULATION
Semaglutide works with GLP-1 receptors that may help regulate appetite signaling. The food noise quiets. Cravings get less constant. Fullness shows up sooner and lasts longer.
SUPPORTS SUSTAINED
METABOLIC HEALTH
In clinical trials, participants experienced meaningful body weight changes with continued use. Your clinician monitors your progress and adjusts to keep you on track. Individual results vary.
ONE SIZE FITS NONE
Personalized protocols, tuned to your body.
Dr. Jonathann Kuo, MD
GLP-1 isn't willpower in a vial. It's a tool. The protocol around it is what determines whether the result holds.
MY STORY
Oliver Woloshin, 47
I had a great experience with Enhanced Games from start to finish. The onboarding process was smooth and straightforward, and I was able to get my first order quickly without any issues.
LOOKING AFTER YOUR APPEARANCE ISN'T VANITY. IT'S MAINTENANCE.
Semaglutide is a clinician-prescribed GLP-1 receptor agonist designed to support appetite regulation and metabolic function. Your protocol is titrated to your tolerance and your goals. Adjusted with ongoing clinical support. Individual results vary.
*Available by prescription only, if medically appropriate.
